Therapeutic-dose heparin appears to benefit noncritically-ill COVID-19 patients, but it does not reduce deaths or other adverse endpoints compared with usual-care thromboprophylaxis if it’s initiated ...
In 97 consecutive patients who received heparin, efficacy, as assessed by a clinically satisfactory response, was not related to sex or age. Adverse reactions occurred in 18 out of 56 women (32 per ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results